Brief: Baxter Changes Reportable Segments To Two Segments Effective Q2 2026 - SEC Filing
BRIEF-Baxter Changes Reportable Segments To Two Segments Effective Q2 2026 - SEC Filing July 14 (Reuters) - SEC Filing:
BAXTER - CHANGES REPORTABLE SEGMENTS TO TWO SEGMENTS EFFECTIVE Q2 2026 - SEC FILING
BAXTER - PHARMACEUTICALS SEGMENT NOW REPORTED WITHIN INFUSION THERAPIES & PLATFORMS DIVISION - SEC FILING
BAXTER - SHARED CORPORATE EXPENSES TO REMAIN UNALLOCATED IN SEGMENT REPORTING - SEC FILING
BAXTER: CHANGES DO NOT IMPACT CO'S PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS EXCEPT FOR ITS SEGMENT DISCLOSURES
Source text: [ID:n0001628280-26-048158]
Further company coverage: BAX.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baxter International
See all newsS&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Press Digest: British Business - August 20
Brief: Baxter Appoints John Rogers Chief Financial Officer
Brief: Baxter Announces Pricing For Its Upsized Cash Tender Offers